Sparfloxacin also is more cost-effective than cefaclor, clarithromycin, and amoxicillin-clavulanic acid as a second-line factor in outpatients in ATS building block I and as a first-line official in patients in ATS abstraction II.
Sparfloxacin therefore dominated the other agents.
The scale value amount expected program cost for sparfloxacin was $42, $81, $130, $172, and $182 less than that for azithromycin, clarithromycin, erythromycin, amoxicillin-clavulanic acid, and cefaclor, respectively.
A greater magnitude relation of patients were treated successfully with sparfloxacin (89.1%) than with azithromycin (79.4%) clarithromycin (77.8%), erythromycin (69.0%), amoxicillin-clavulanic acid (70.8%), and cefaclor (73.0%).
This quality in efficacy is based on considerable lot rates for the other drugs associated with isolate ohmic resistance to initial empiric therapy.
These results, when viewed from the appearance of a payer with a age bracket of 100 patients, suggest that initial therapy with sparfloxacin would cost $4200 less than azithromycin to dainty 10 additional patients successfully, $8100 less than clarithromycin to aliment 11 additional patients, $13,000 less than erythromycin to victuals an additional 20 patients, $17,200 less than amoxicillin-clavulanic acid to occurrent 18 additional patients, and $18,200 less than cefaclor to kickshaw 20 additional patients.
This, in validity, instrumentality that payers would realize net cost savings substituting sparfloxacin for the comparator drugs.
Sensibility AnalysesVariables altered in the sensibility criticism included somebody rates of all antibiotics against medicine etiologic organisms, rate of the causative organisms, quality of a film taste, and cost of drugs.
Cost-effectiveness results were sensitive to changes in several variables, especially to the successfulness rate against UBO for azithromycin, clarithromycin, and erythromycin.
Both clarithromycin and erythromycin would have been more cost-effective than sparfloxacin if their efficacy against UBO were greater than 97.8%.
Azithromycin would have been the most cost-effective if its efficacy against UBO was greater than 93.0%.
Azithromycin also would have been more cost-effective than sparfloxacin if the true positive degree rate of a sputum development were less than 32.1%.
Cost-effectiveness results were not sensitive to changes in any other star.
This is a part of article Cost-Effectiveness of Sparfloxacin Compared With Other. Taken from "Ceclor Cefaclor Info" Information Blog